Key Takeaways:
Angelalign expects interim net profit of USD 24-25.4 million, up 69%-78.9% year on year, as clear aligner demand accelerates.
Management attributed the jump to growing preference among clinicians for clinically proven aligners and the payoff from years of investment in global direct sales and localized clinical support, which are now delivering operating leverage. The company also cited an open, multinational innovation culture that is strengthening brand recognition in both overseas and Chinese markets.
Revenue for the first half is expected to range between USD 229 million and USD 231 million, up 41.9% to 43.1% year on year. Clear aligner case volume is set to rise about 40% to roughly 316,600, with a growing presence in adolescent and paediatric patient segments. The company serves dental professionals across mainland China and global markets through direct sales and localized clinical support teams.
Shares of the Shanghai-based orthodontics provider opened 8.2% higher and peaked at HKD 97, up 21.4%, before trading at HKD 93.6, up 17.15%, with turnover of HKD 160 million. Short selling accounted for 17% of the day's activity. The stock carries a market capitalization of HK$13.68 billion and holds a Buy rating with a HK$91.89 price target from analysts covering the name.
The profit alert marks the latest sign of strength in the clear aligner market, where Angelalign competes with Align Technology's Invisalign and Straumann. The guidance implies the company is gaining share as clinicians shift toward clinically validated products backed by direct-sales support, a model that has proven harder for rivals to replicate in China's fragmented dental market.
For holders, the acceleration in case volume and revenue points to sustained operating leverage as fixed costs spread across a larger base. Investors will watch the full interim results, expected in August, for margin details and any update on the adolescent segment's contribution, which management has flagged as a key growth driver.
This article is for informational purposes only and does not constitute investment advice.
